• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

F5-Atlanta:与增强型东德克萨斯 splicing 和 FV-短产生相关的 F5 中的新型突变。

F5-Atlanta: A novel mutation in F5 associated with enhanced East Texas splicing and FV-short production.

机构信息

Aflac Cancer and Blood Disorders Center, Emory University/Children's Healthcare of Atlanta, Atlanta, Georgia, USA.

The Children's Hospital of Philadelphia, The Raymond G. Perelman Center for Cellular and Molecular Therapeutics, Philadelphia, Pennsylvania, USA.

出版信息

J Thromb Haemost. 2021 Jul;19(7):1653-1665. doi: 10.1111/jth.15314. Epub 2021 May 20.

DOI:10.1111/jth.15314
PMID:33773040
Abstract

BACKGROUND

Elucidating the molecular pathogenesis underlying East Texas bleeding disorder (ET) led to the discovery of alternatively spliced F5 transcripts harboring large deletions within exon 13. These alternatively spliced transcripts produce a shortened form of coagulation factor V (FV) in which a large portion of its B-domain is deleted. These FV isoforms bind tissue factor pathway inhibitor alpha (TFPIα) with high affinity, prolonging its circulatory half-life and enhancing its anticoagulant effects. While two missense pathogenic variants highlighted this alternative splicing event, similar internally deleted FV proteins are found in healthy controls.

OBJECTIVE

We identified a novel heterozygous 832 base pair deletion within F5 exon 13, termed F5-Atlanta (F5-ATL), in a patient with severe bleeding. Our objective is to investigate the effect of this deletion on F5 and FV expression.

METHODS & RESULTS: Assessment of patient plasma revealed markedly elevated levels of total and free TFPI and a FV isoform similar in size to the FV-short described in ET. Sequencing analyses of cDNA revealed the presence of a transcript alternatively spliced using the ET splice sites, thereby removing the F5-ATL deletion. This alternative splicing pattern was recapitulated by heterologous expression in mammalian cells.

CONCLUSIONS

These findings support a mechanistic model consisting of cis-acting regulatory sequences encoded within F5 exon 13 that control alternative splicing at the ET splice sites and thereby regulate circulating FV-short and TFPIα levels.

摘要

背景

阐明导致东德克萨斯出血性疾病(ET)的分子发病机制,发现了 F5 转录本的选择性剪接,该转录本在exon13 内含有大片段缺失。这些选择性剪接的转录本产生凝血因子 V(FV)的缩短形式,其中其 B 结构域的大部分被缺失。这些 FV 同工型与组织因子途径抑制剂 α(TFPIα)具有高亲和力结合,延长其循环半衰期并增强其抗凝作用。虽然两种错义致病性变异突出了这种选择性剪接事件,但在健康对照中也发现了类似的内部缺失 FV 蛋白。

目的

我们在一名严重出血的患者中鉴定出 F5exon13 内的一个新的杂合 832 碱基对缺失,称为 F5-Atlanta(F5-ATL)。我们的目的是研究该缺失对 F5 和 FV 表达的影响。

方法和结果

对患者血浆的评估显示总 TFPI 和游离 TFPI 水平显著升高,FV 同工型大小与 ET 中描述的 FV-short 相似。cDNA 的测序分析显示存在使用 ET 剪接位点进行选择性剪接的转录本,从而去除了 F5-ATL 缺失。这种选择性剪接模式通过在哺乳动物细胞中的异源表达得到重现。

结论

这些发现支持一个机制模型,该模型由 F5exon13 内编码的顺式作用调节序列组成,控制 ET 剪接位点的选择性剪接,从而调节循环 FV-short 和 TFPIα 水平。

相似文献

1
F5-Atlanta: A novel mutation in F5 associated with enhanced East Texas splicing and FV-short production.F5-Atlanta:与增强型东德克萨斯 splicing 和 FV-短产生相关的 F5 中的新型突变。
J Thromb Haemost. 2021 Jul;19(7):1653-1665. doi: 10.1111/jth.15314. Epub 2021 May 20.
2
Factor V east Texas variant causes bleeding in a three-generation family.因子 V 东得克萨斯变异导致三代家系出血。
J Thromb Haemost. 2022 Mar;20(3):565-573. doi: 10.1111/jth.15612. Epub 2021 Dec 7.
3
Coagulation factor V(A2440G) causes east Texas bleeding disorder via TFPIα.凝血因子 V(A2440G) 通过 TFPIα 导致东德克萨斯出血性疾病。
J Clin Invest. 2013 Sep;123(9):3777-87. doi: 10.1172/JCI69091. Epub 2013 Aug 27.
4
Characterization of an apparently synonymous F5 mutation causing aberrant splicing and factor V deficiency.一个导致异常剪接和因子V缺乏的明显同义F5突变的特征分析。
Haemophilia. 2015 Mar;21(2):241-248. doi: 10.1111/hae.12554. Epub 2014 Dec 3.
5
Factor V, tissue factor pathway inhibitor, and east Texas bleeding disorder.凝血因子 V、组织因子途径抑制剂与东得克萨斯出血性疾病。
J Clin Invest. 2013 Sep;123(9):3710-2. doi: 10.1172/JCI71220. Epub 2013 Aug 27.
6
Pro- and anticoagulant properties of factor V in pathogenesis of thrombosis and bleeding disorders.凝血因子V的促凝和抗凝特性在血栓形成和出血性疾病发病机制中的作用
Int J Lab Hematol. 2016 May;38 Suppl 1:4-11. doi: 10.1111/ijlh.12508. Epub 2016 May 9.
7
Novel insights into the regulation of coagulation by factor V isoforms, tissue factor pathway inhibitorα, and protein S.新型因子 V 异构体、组织因子途径抑制物α 和蛋白 S 对凝血的调控作用的新见解。
J Thromb Haemost. 2017 Jul;15(7):1241-1250. doi: 10.1111/jth.13665.
8
Molecular characterization of three novel splicing mutations causing factor V deficiency and analysis of the F5 gene splicing pattern.导致因子V缺乏的三种新型剪接突变的分子特征及F5基因剪接模式分析
Haematologica. 2008 Oct;93(10):1505-13. doi: 10.3324/haematol.12934. Epub 2008 Aug 25.
9
The common VTE-protective G haplotype of F5 increases factor V-short, TFPI function, and risk of bleeding.凝血因子V常见的VTE保护性G单倍型增加了凝血因子V短链、组织因子途径抑制物(TFPI)的功能以及出血风险。
Blood Adv. 2025 Jan 14;9(1):132-142. doi: 10.1182/bloodadvances.2024014020.
10
Homozygous F5 deep-intronic splicing mutation resulting in severe factor V deficiency and undetectable thrombin generation in platelet-rich plasma.纯合 F5 内含子剪接突变导致严重的因子 V 缺乏和富含血小板血浆中无法检测到的凝血酶生成。
J Thromb Haemost. 2011 May;9(5):959-68. doi: 10.1111/j.1538-7836.2011.04237.x.

引用本文的文献

1
Placental Vascular Defects and Embryonic Lethality Triggered by TFPIα Deficiency in Factor V Leiden Mice.因子V莱顿小鼠中TFPIα缺乏引发的胎盘血管缺陷和胚胎致死性
Arterioscler Thromb Vasc Biol. 2025 Jul;45(7):1266-1276. doi: 10.1161/ATVBAHA.125.322650. Epub 2025 May 22.
2
Basic regions of factor V and tissue factor pathway inhibitor mediate heavy chain and acidic region interactions on factor V revealed by tethered chemical cleavage.通过连接化学切割揭示的凝血因子V和组织因子途径抑制剂的基本区域介导凝血因子V重链与酸性区域的相互作用。
J Thromb Haemost. 2025 Aug;23(8):2449-2460. doi: 10.1016/j.jtha.2025.04.028. Epub 2025 May 12.
3
The common VTE-protective G haplotype of F5 increases factor V-short, TFPI function, and risk of bleeding.
凝血因子V常见的VTE保护性G单倍型增加了凝血因子V短链、组织因子途径抑制物(TFPI)的功能以及出血风险。
Blood Adv. 2025 Jan 14;9(1):132-142. doi: 10.1182/bloodadvances.2024014020.
4
Tissue factor pathway inhibitor - cofactor-dependent regulation of the initiation of coagulation.组织因子途径抑制剂 - 辅因子依赖性调节凝血的启动。
Curr Opin Hematol. 2024 Nov 1;31(6):315-320. doi: 10.1097/MOH.0000000000000838. Epub 2024 Aug 26.
5
Factor V variants in bleeding and thrombosis.出血和血栓形成中的凝血因子V变体
Res Pract Thromb Haemost. 2024 Jan 26;8(1):102330. doi: 10.1016/j.rpth.2024.102330. eCollection 2024 Jan.
6
Platelet tissue factor pathway inhibitor-α dampens cardiac thrombosis and associated fibrosis in mice.血小板组织因子途径抑制剂-α可抑制小鼠心脏血栓形成和相关纤维化。
J Thromb Haemost. 2023 Mar;21(3):639-651. doi: 10.1016/j.jtha.2022.11.034. Epub 2022 Dec 22.
7
Tissue factor pathway inhibitor is a potential modifier of bleeding risk in factor XI deficiency.组织因子途径抑制剂是因子 XI 缺乏症出血风险的潜在调节剂。
J Thromb Haemost. 2023 Mar;21(3):467-479. doi: 10.1016/j.jtha.2022.10.005. Epub 2022 Dec 22.
8
Regulation of coagulation by tissue factor pathway inhibitor: Implications for hemophilia therapy.组织因子途径抑制剂对凝血的调节:对血友病治疗的影响。
J Thromb Haemost. 2022 Jun;20(6):1290-1300. doi: 10.1111/jth.15697. Epub 2022 Mar 27.
9
A hydrophobic patch (PLVIVG; 1481-1486) in the B-domain of factor V-short is crucial for its synergistic TFPIα-cofactor activity with protein S and for the formation of the FXa-inhibitory complex comprising FV-short, TFPIα, and protein S.FV 短链 B 结构域中的疏水性补丁(PLVIVG;1481-1486)对于其与蛋白 S 的协同 TFPIα 辅因子活性以及 FXa 抑制性复合物的形成至关重要,该复合物包含 FV 短链、TFPIα 和蛋白 S。
J Thromb Haemost. 2022 May;20(5):1146-1157. doi: 10.1111/jth.15690. Epub 2022 Mar 16.
10
Factor V east Texas variant causes bleeding in a three-generation family.因子 V 东得克萨斯变异导致三代家系出血。
J Thromb Haemost. 2022 Mar;20(3):565-573. doi: 10.1111/jth.15612. Epub 2021 Dec 7.